Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00834_DB08895_nanopub.RAobN71urG9843TxSVpniEgUJ9o35z_zeqw7e-eD1Ke2k#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00834_DB08895 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00834_DB08895 label "DDI between Mifepristone and Tofacitinib - Mifepristone, when used in combination with tofacitinib, may increase tofacitinib concentrations. It is recommended to adjust therapy by using a minimized dose of tofacitinib, and monitoring for increased tofacitinib concentrations and signs of toxicity, during and 2 weeks after discontinuation of mifepristone therapy. [drugbank_resource:DB00834_DB08895]" assertion.
- drugbank_resource:DB00834_DB08895 identifier "drugbank_resource:DB00834_DB08895" assertion.
- drugbank_resource:DB00834_DB08895 title "DDI between Mifepristone and Tofacitinib - Mifepristone, when used in combination with tofacitinib, may increase tofacitinib concentrations. It is recommended to adjust therapy by using a minimized dose of tofacitinib, and monitoring for increased tofacitinib concentrations and signs of toxicity, during and 2 weeks after discontinuation of mifepristone therapy." assertion.
- drugbank:DB08895 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00834_DB08895 assertion.
- drugbank:DB00834 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00834_DB08895 assertion.